Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14
In spite of the increasing scientific interest to understand how cannabinoids can help to treat cancer disease, symptoms and the associated chemotherapy side effects, the existing scientific evidence is not enough to satisfy the clinical criteria to consider cannabinoids as a part of the treatment.
Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14
Bone cancers result from primary tumor invasion to bone. cannabinoids can be used to relieve Bone Cancer pain through their anti-inflammatory properties and also they could be used to treat cancer itself.
Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14
Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14
Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14
Glioblastoma is a malignant brain tumor originated in brain cells called astrocytes. Glioblastoma is one of the most promising targets for cannabinoid therapy. Several research groups found anti-tumor properties of cannabinoids in vitro and in vivo studies.
Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14
leukemia cancers usually begin in the bone marrow and involves abnormal white blood cell production.
Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14
Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14
cannabinoids have excellent therapeutic potential for the treatment of epilepsy. In the brain, the endocannabinoid system tends to keep neuronal activity wihtin acceptable boundaries.
Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14
pparγ is part of the nuclear receptor family and one of the non-GPCR cannabinoid receptors. pparγ is involved in the regulation of fat cells/adipose tissue, insulin sensitivity and inflammation.
Submitted by heiko@ghsctradi... on Mon, 03/14/2016 - 13:14
CB2 is primarily expressed in the immune cells and tissues of the body. Like CB1, CB2 is a G protein-coupled receptor which inhibits adenylyl cyclase and consequently lowers cAMP upon activation. This, in turn, regulates many second messenger pathways.